Rigel Pharmaceuticals (RIGL) Cost of Revenue (2018 - 2026)

Rigel Pharmaceuticals' Cost of Revenue history runs 9 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 4.47% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $19.8 million (down 5.77% YoY), while the FY2025 annual figure was $19.6 million, up 5.22% from the prior year.
• Cost of Revenue for Q1 2026 stood at $4.6 million, down from $6.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $8.0 million in Q3 2024, with the low at $121000.0 in Q1 2022.
• The 5-year median for Cost of Revenue is $2.8 million (2024), against an average of $3.0 million.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue plunged 61.71% in 2022, then jumped 1008.19% in 2023.
• Rigel Pharmaceuticals' Cost of Revenue stood at $342000.0 in 2022, then surged by 1008.19% to $3.8 million in 2023, then surged by 52.74% to $5.8 million in 2024, then gained by 2.87% to $6.0 million in 2025, then fell by 22.65% to $4.6 million in 2026.
• Business Quant data shows RIGL's Cost of Revenue at $4.6 million in Q1 2026, $6.0 million in Q4 2025, and $4.8 million in Q3 2025.